Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.
The company’s teplizumab delays development of type 1 diabetes, but Lilly’s failure with the same project nine years earlier casts a long shadow.